New Releases from NCBI BookshelfApalutamide with androgen deprivation therapy for treating high-risk hormone-relapsed non-metastatic prostate cancer.​Apalutamide with androgen deprivation therapy for treating high-risk hormone-relapsed non-metastatic prostate cancer.